Artelo Biosciences receives USPTO notice of allowance for lead drug
Artelo Biosciences (ARTL) says it receives a Notice of Allowance from the U.S. Patent and Trademark Office for its lead investigational drug currently in two Phase 2 studies.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.